Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product.
Solural Pharma will continue to support Ascelia Pharma with chemistry manufacturing and control services.
- Updated Manufacturing and Importation Authorisation February 13, 2018
- Solural Pharma gets a European patent August 9, 2017
- Ascelia Pharma AB acquires Oncoral Pharma ApS June 30, 2017